(Bloomberg) -- Novo Nordisk A/S plans to invest €2.1 billion ($2.3 billion) to expand production in France as it works to meet surging demand for its sought-after weight-loss medicines.

Novo Nordisk's weight loss drug Wegovy will be available in France from Tuesday. The drug will require a prescription and will not be covered by social security.

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by ...

Danish pharmaceutical giant Novo Nordisk sees a significant increase in profits and sales despite production constraints.

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical ...

France, and Argentina. UVA and Novo Nordisk will initially dedicate around 15 employees to the collaboration and expect the support to grow as the research develops. Kenneth Strømdahl ...

3️⃣ Poignant postcard: In 1912, a first-class passenger on the Titanic scrawled a message in pencil to someone back home in ...

For U.S. investors who are worried that domestic stocks are overheated and have gotten too expensive, the iShares Core MSCI ...

After a Montana man illegally cloned and bred an endangered giant sheep species, government agencies must now contend with ...

Novo Nordisk is ramping up its manufacturing sites ... which has been approved for use to treat obesity in Britain, Denmark, France, Germany, Norway and the United States, rose by 42 percent ...